- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06259409
Regenn® Therapy System Safety Study
A Randomized Clinical Study Evaluating the Safety of Regenn® Negative Pressure Therapy System in Orthopaedic Surgical Wound Management
The goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are:
- The device-related serious adverse event rate.
- Patient post-operative pain as assessed using a validated pain measurement scoring system.
- The number and type of adverse events.
- The rate of delayed seroma formation.
Participants will
- Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications.
- Undergo a physical exam, an assessment of patient vital signs and routine blood analyses.
- Complete an Informed Consent Form if selected to participate in the investigational study.
- Be randomly assigned to the different study arms.
- Not change the operation of their respective device or to disturb components of their device.
- Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device.
- Attend two post-operative visits at approximately one month and three months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Neal K Vail, PhD
- Phone Number: 2 (844) 977-6436
- Email: clinical@progenerative.com
Study Contact Backup
- Name: James W Poser, PhD
- Phone Number: 1 (844) 977-6436
- Email: clinical@progenerative.com
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- The University of Kansas Medical Center
-
Contact:
- Stephanie Robinson, MS
- Phone Number: 913-588-0581
- Email: srobinson6@kumc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria (must meet ALL):
- Subject has provided written informed consent on a form reviewed and approved by the Institutional Review Board for the clinical site.
- The subject is 18 - 80 years old.
The subject has Spondylolisthesis of Meyerding Grade II or less, or has Degenerative Disc Disease (DDD) accompanied by back pain with or without leg pain at a level between L1 and S1 confirmed by history and radiographic assessment. DDD is determined to be present if one or more of the following are noted:
- Instability (defined as angulation ≥ 5 degrees and/or translation ≥ 3mm on flexion/extension radiographs;
- Osteophyte formation of facet joints or vertebral endplates;
- Decreased disc height, on average by >2mm, but dependent upon the spinal level;
- Scarring / thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule;
- Herniated nucleus pulposus;
- Facet joint degeneration / changes; and/or
- Vacuum phenomenon.
- Female subjects of childbearing potential must not be pregnant or nursing and must agree to use of contraception for the study duration. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test and birth control.
- The subject is willing and able to comply with the protocol mandated follow-up visits and testing regimen.
Exclusion Criteria (candidates meeting ANY of the following at the time of the study procedure are NOT eligible):
- Subject is unable or unwilling to provide informed consent or is unable to conform to the study protocol follow-up procedures and visits.
- Subject has a contraindication (including allergic reaction) to antiplatelet/anticoagulant medications, nickel, titanium, bone allograft, or blood transfusion that is not amenable to pretreatment with steroids or/and antihistamines.
- Subject has a history of bleeding diatheses or coagulopathy.
- Subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or any autoimmune diseases.
- Subject is receiving dialysis or immunosuppressive therapy.
- Subject suffered a hemorrhagic stroke < 6 months prior to the study procedure.
- Subject is undergoing spinal surgery for vertebral fracture, trauma, or scoliosis.
- Subject has any form of active malignancy.
- Subject is an intravenous drug user and/or alcoholic.
- Subject is diagnosed with septicemia at the time of the study procedure.
- Subject is a smoker.
- Subject has Type I diabetes.
- Subject has overt, uncontrolled Type II diabetes.
- Subject has a condition requiring postoperative medications that would be expected to interfere with fusion (e.g., steroids), or has received drugs that interfere with bone metabolism within 2 weeks of the surgery.
- Subject is suffering from gross obesity, defined as > 40% IBW.
- Subject exhibits Waddell signs of Inorganic Behavior ≥ 3.
- Subject has had a previous, anterior spinal fusion, interbody spinal fusion, or posterior spinal instrumentation at the involved level.
- Subject has another medical condition, which may cause them to be non-compliant with the protocol, confound the data interpretation, or is associated with limited life expectancy of less than two years.
- Subject has a systemic disease of connective tissue such as Rheumatoid Arthritis, or Ankylosing Spondylitis.
- Subject is a prisoner.
- Subject is currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
This group will receive the study device, Regenn® Negative Pressure Therapy System, a form of Negative Pressure Wound Therapy (NPWT).
Regenn® Therapy manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum).
Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by an attached small, dressing that the surgeon places in the surgical wound at the end of the surgery.
Reduced pressure therapy is applied while the patient recovers from surgery.
|
Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
Other Names:
|
Active Comparator: Control Arm
This group will receive the control device, also a form of Negative Pressure Wound Therapy (NPWT), which manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum).
Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by a small tube connected to a wound dressing placed over the closed surgical wound at the end of the surgery.
Reduced pressure therapy is applied while the patient recovers from surgery.
|
Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device-related Serious Adverse Event Rate
Time Frame: Post-operative follow ups at 2-8 weeks and 3-6 months.
|
The device-related serious adverse event rate associated with the use of the investigational device and the comparator device.
Wound complications requiring surgical intervention, such as wound dehiscence, will be the primary indicator of blood supply at the wound site, damage to the surrounding tissue, and progression of wound healing.
|
Post-operative follow ups at 2-8 weeks and 3-6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative Pain Profile
Time Frame: Post-operative up to the 3-6 month follow up visit.
|
Post-operative pain will be assessed using the Numerical Rating Scale (NRS), a validated pain measurement scoring system with a pain rating scale of 0 - 10, where zero means "No pain" and 10 means "The worst pain imaginable"
|
Post-operative up to the 3-6 month follow up visit.
|
Adverse Events Related to the Investigational Device
Time Frame: Post-operative follow ups at approximately one month and three months.
|
The number and type of adverse events associated with the use of the investigational device.
Assessment will include wound complications not requiring surgical intervention, device complications, medical complications and infections complications.
|
Post-operative follow ups at approximately one month and three months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delayed Seroma Formation Rate
Time Frame: Post-operative follow up at 2-8 weeks (at the surgeon's discretion) and at 3-6 months (required).
|
Delayed seroma formation will be assessed by ultrasound imaging during post-operative follow up visits.
|
Post-operative follow up at 2-8 weeks (at the surgeon's discretion) and at 3-6 months (required).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Doc-0353
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Wound
-
St. Borbala HospitalSemmelweis University; Department of Surgery, Jahn Ferend Dél-Pesti Kórház... and other collaboratorsTerminatedSurgical Wound | Surgical Site Infection | Wound Dehiscence, Surgical | Dehiscence of Internal Surgical WoundHungary
-
ConvaTec Inc.WithdrawnSurgical Wound, Recent | Trauma-related Wound | Dehiscence Wound | Surgical Wound LeakUnited States
-
Centro Hospitalar do Tâmega e SousaActive, not recruitingSurgical Wound | Surgical Wound Infection | Surgical Site Infection | Surgical Wound, Healed | Surgical Complication | Surgical Wound Dehiscence | Surgical Wound HaemorrhagePortugal
-
Molnlycke Health Care ABSyntactxNot yet recruitingSurgical Wound | Surgical Incision | Surgical Wound Dehiscence | Incision, Surgical | Surgical Wound, Recent
-
Associazione Infermieristica per lo studio delle...Unknown
-
Brock Liden, DPMWithdrawnSurgical Wound, HealedUnited States
-
University of California, DavisCompletedSurgical Wound Cosmesis
-
HITEC-Institute of Medical SciencesCompletedWound Infection | Wound Dehiscence | Wound Surgical | Wound BleedingPakistan
-
Abouqir General HospitalAlexandria UniversityCompletedSurgical Wound Closure TechniqueEgypt
-
Chulalongkorn UniversityUnknownWound Heal | Wound Surgical | Donor Site ComplicationThailand
Clinical Trials on Regenn® Negative Pressure Therapy System
-
ConvaTec Inc.WithdrawnSurgical Wound, Recent | Trauma-related Wound | Dehiscence Wound | Surgical Wound LeakUnited States
-
3MCompletedDiabetic Foot UlcersUnited States
-
University of Witten/HerdeckeKCI Europe Holding B.V.CompletedImpaired Wound Healing | Wound Healing Disorder | Abdominal Wound Healing Disorder | Abdominal Wound Healing Impairment | Acute Postsurgical Subcutaneous WoundBelgium, Germany
-
DeRoyal Industries, Inc.Lincoln Memorial UniversityCompletedSkin Sensitisation | Skin Reaction to Mechanical, Thermal and Radiation StimuliUnited States
-
Fundación Pública Andaluza para la gestión de la...Not yet recruitingInfection, Surgical Site
-
Badr UniversityUnknownChronic Ulcers | Negative Pressure TherapyEgypt
-
Chang Gung Memorial HospitalCompleted
-
Murk NiazCompletedSurgical Site Infection | Hepatobiliary Disease | Hepatobiliary DisordersPakistan
-
Zuyderland Medisch CentrumCompletedBreast Cancer | Wound Infection | Wound Complication | Wound Dehiscence | Wound NecrosisNetherlands